BR112013028808A2 - métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada - Google Patents

métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada

Info

Publication number
BR112013028808A2
BR112013028808A2 BR112013028808A BR112013028808A BR112013028808A2 BR 112013028808 A2 BR112013028808 A2 BR 112013028808A2 BR 112013028808 A BR112013028808 A BR 112013028808A BR 112013028808 A BR112013028808 A BR 112013028808A BR 112013028808 A2 BR112013028808 A2 BR 112013028808A2
Authority
BR
Brazil
Prior art keywords
therapy
therapeutic
disease activity
personalized
management
Prior art date
Application number
BR112013028808A
Other languages
English (en)
Inventor
Nicholas Hoe
Scott Hauenstein
Sharat Singh
Steve Lockton
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013028808A2 publication Critical patent/BR112013028808A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

resumo patente de invenção: "métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada". a presente invenção proporciona métodos para a gestão terapêutica personalizada de uma doença a fim de otimizar a terapia e/ou monitorar a eficácia terapêutica. em particular, a presente invenção compreende medição de um arranjo de um ou uma pluralidade de biomarcadores em uma pluralidade de pontos no tempo ao longo do curso de terapia com um agente terapêutico para determinar um índice de cicatrização mucosal para seleção de terapia, otimização de terapia, redução de toxicidade e/ou monitoramento de eficácia do tratamento terapêutico. em determinados casos, o agente terapêutico é um inibidor de tnf? para o tratamento de uma doença ou distúrbio mediado por tnf.
BR112013028808A 2011-05-10 2012-05-10 métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada BR112013028808A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161484607P 2011-05-10 2011-05-10
US201161505026P 2011-07-06 2011-07-06
US201161553909P 2011-10-31 2011-10-31
US201161566509P 2011-12-02 2011-12-02
US201261636575P 2012-04-20 2012-04-20
PCT/US2012/037375 WO2012154987A1 (en) 2011-05-10 2012-05-10 Methods of disease activity profiling for personalized therapy management

Publications (1)

Publication Number Publication Date
BR112013028808A2 true BR112013028808A2 (pt) 2016-09-06

Family

ID=46147068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028808A BR112013028808A2 (pt) 2011-05-10 2012-05-10 métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada

Country Status (14)

Country Link
US (3) US10086072B2 (pt)
EP (1) EP2707504A1 (pt)
JP (3) JP2014517279A (pt)
KR (1) KR20140032424A (pt)
CN (2) CN110544517A (pt)
AU (1) AU2012253422B2 (pt)
BR (1) BR112013028808A2 (pt)
CA (1) CA2839792A1 (pt)
IL (1) IL229120B (pt)
MX (2) MX362132B (pt)
RU (1) RU2013154566A (pt)
SG (1) SG194710A1 (pt)
WO (1) WO2012154987A1 (pt)
ZA (1) ZA201309258B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
US20140205613A1 (en) * 2013-01-21 2014-07-24 Abbvie Inc. Anti-tnf and anti-il 17 combination therapy biomarkers for inflammatory disease
US9878010B2 (en) 2013-03-21 2018-01-30 The Regents Of The University Of Michigan Methods of treating metabolic disorders
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
US10846371B2 (en) * 2014-04-10 2020-11-24 Yissum Research Development Company of the Hebrew University of Jerusalm Ltd. Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US20170105647A1 (en) * 2014-05-15 2017-04-20 Children's Medical Center Corporation Systems and methods for identifying neurobiological biomarkers using eeg
EP3210016A1 (en) 2014-10-20 2017-08-30 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
CA2969326A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
RU2017122720A (ru) 2014-12-05 2019-01-10 Нестек С.А. Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента
EP3309553A4 (en) * 2015-06-09 2019-02-13 Osaka University METHOD OF PREDICTING / EVALUATING THE THERAPEUTIC EFFECT OF BIOLOGICAL PREPARATION ON RHEUMATOID ARTHRITIS
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
KR20220153109A (ko) 2016-03-17 2022-11-17 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
JP2019514939A (ja) * 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 標的組織における自然免疫応答の治療的誘発
KR20190016972A (ko) 2016-05-20 2019-02-19 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
EP3529379B1 (en) 2016-10-24 2022-05-18 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO System and method for implementing meal selection based on vitals, genotype, and phenotype
WO2018085937A1 (en) * 2016-11-14 2018-05-17 Qu Biologics Inc. Managing site specific ibd immunotherapies
CN110622179A (zh) * 2017-02-09 2019-12-27 科格诺亚公司 用于数字个性化医疗的平台和系统
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
EP3695229A1 (en) 2017-10-10 2020-08-19 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
US11270800B1 (en) * 2017-11-09 2022-03-08 Aptima, Inc. Specialized health care system for selecting treatment paths
MX2019003148A (es) * 2017-11-13 2019-05-27 The Multiple Myeloma Res Foundation Inc Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados.
JP2021518432A (ja) 2018-03-16 2021-08-02 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
KR20240031439A (ko) 2019-03-22 2024-03-07 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
CN109998488B (zh) * 2019-04-13 2022-08-02 中国医学科学院北京协和医院 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法
BR112021022789A2 (pt) 2019-05-14 2022-04-19 Cedars Sinai Medical Center Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
CA3145237A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
CA3233288A1 (en) * 2021-09-30 2023-04-06 Prometheus Laboratories Inc. Patient centric precision model for anti-tnf therapy
WO2023064437A1 (en) * 2021-10-15 2023-04-20 The Trustees Of Indiana University Methods for detecting fracture-related infection (fri)
US11887720B1 (en) * 2023-01-23 2024-01-30 Kpn Innovations, Llc Apparatus and method for using a feedback loop to optimize meals

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262493A1 (en) 1992-10-29 2002-12-04 Bayer Corporation Diagnostic assay for latent matrix metalloproteinase no. 9
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ES2148251T3 (es) 1993-03-10 2000-10-16 Cedars Sinai Medical Center Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria.
US20020025553A1 (en) 1996-01-04 2002-02-28 Ying-Fei Wei Transforming growth factor alpha HIII
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6319899B1 (en) 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
RU2141332C1 (ru) 1998-06-24 1999-11-20 Научно-исследовательский институт фармакологии Томского научного центра РАМН Противоязвенное средство и способ его получения
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
JP2004528814A (ja) 2000-10-13 2004-09-24 チルドレンズ メディカル センター コーポレーション 組織再構築関連状態についての非侵襲性酵素スクリーニング
WO2002036773A2 (en) 2000-10-30 2002-05-10 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
AU2002243415B2 (en) 2000-10-30 2007-05-24 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
US7192724B2 (en) 2000-11-14 2007-03-20 Techlab, Inc. Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker
CA2458667A1 (en) 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Educat Ion Of Pennsylvania Method for predicting the outcome of an infection
US20050154536A1 (en) 2001-08-30 2005-07-14 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Two-part drug discovery system
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
CA2502976C (en) 2002-10-25 2012-05-22 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2005009339A2 (en) 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
KR20060022289A (ko) 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
US7439019B2 (en) 2003-11-03 2008-10-21 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction
CN1956738B (zh) 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
FI119572B (fi) 2004-03-05 2008-12-31 Biohit Oyj Menetelmä vatsan limakalvon tilan ennustamiseksi
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
EP1810198A1 (en) 2004-09-09 2007-07-25 Université de Liège Identification and use of biomarkers for the diagnosis and the prognosis of inflammatory diseases.
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
HUE036973T2 (hu) 2005-10-26 2018-08-28 Novartis Ag Örökletes mediterrán láz kezelése anti-IL-1 béta antitestekkel
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
MX2009003048A (es) 2006-09-21 2009-09-07 Prometheus Lab Inc Disposiciones a base de anticuerpo para detectar transductores de multiple señal en celulas circulantes raras.
US8165819B2 (en) 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US20100255513A1 (en) 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
GB2447865A (en) 2007-03-30 2008-10-01 Ethicon Inc Diagnostic markers of wound infection
EP2160475A4 (en) 2007-05-22 2011-02-09 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS
CA2693013A1 (en) 2007-07-13 2009-01-22 Prometheus Laboratories Inc. Drug selection for lung cancer therapy using antibody-based arrays
CN102016581B (zh) 2008-02-25 2014-07-30 雀巢产品技术援助有限公司 用抗体阵列选择乳腺癌治疗药物
KR101806432B1 (ko) 2008-03-26 2017-12-07 테라노스, 인코포레이티드 임상 결과를 평가하기 위한 방법 및 시스템
EP2307563B1 (en) * 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosal gene signatures
EP2326731B1 (en) * 2008-08-25 2013-11-13 Janssen Biotech, Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
CA2734519C (en) * 2008-08-29 2018-11-13 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
WO2010127057A2 (en) 2009-05-01 2010-11-04 Meso Scale Technologies, Llc. Biomarkers of therapeutic responsiveness
AU2010248884B2 (en) 2009-05-14 2015-04-02 Nestec S.A. Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
WO2010151699A1 (en) 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EP2488659B1 (en) * 2009-10-15 2019-12-11 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring inflammatory disease activity
WO2011050069A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
WO2011066458A2 (en) 2009-11-25 2011-06-03 Prometheus Laboratories Inc. Novel genomic biomarkers for irritable bowel syndrome diagnosis
US20130071860A1 (en) 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`
CA2801575A1 (en) 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
EP2606353A4 (en) 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
SG10201510086VA (en) 2010-12-23 2016-01-28 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
MX352274B (es) 2011-10-21 2017-11-16 Nestec Sa Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
EP2819697A4 (en) 2012-02-29 2016-03-09 Gilead Biologics Inc ANTIBODIES AGAINST METALLOPROTEINASE 9 OF MATRIX
MX358730B (es) 2012-10-05 2018-09-03 Nestec Sa Metodos para predecir y monitorear cicatrizacion de la mucosa.
US20140113306A1 (en) 2012-10-17 2014-04-24 Rutgers, The State University Of New Jersey Diagnostic and screening methods for inflammation
CN105247370A (zh) 2013-01-03 2016-01-13 梅索磅秤技术有限公司 测定实验对象组
US20140236166A1 (en) 2013-02-15 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
JP2018504405A (ja) 2015-01-23 2018-02-15 ネステク ソシエテ アノニム Ｉｂｄ患者の治療に有用な栄養組成物
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
WO2020117795A1 (en) 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease

Also Published As

Publication number Publication date
AU2012253422A1 (en) 2013-05-02
NZ617009A (en) 2015-09-25
JP2020098213A (ja) 2020-06-25
US20190060449A1 (en) 2019-02-28
CA2839792A1 (en) 2012-11-15
MX2018008324A (es) 2021-11-16
KR20140032424A (ko) 2014-03-14
WO2012154987A1 (en) 2012-11-15
AU2012253422B2 (en) 2015-08-13
RU2013154566A (ru) 2015-06-20
US20220096629A1 (en) 2022-03-31
CN103649336A (zh) 2014-03-19
JP2014517279A (ja) 2014-07-17
MX2013013096A (es) 2014-07-14
JP2018072349A (ja) 2018-05-10
ZA201309258B (en) 2016-08-31
MX362132B (es) 2019-01-07
IL229120A0 (en) 2013-12-31
CN110544517A (zh) 2019-12-06
US11160863B2 (en) 2021-11-02
SG194710A1 (en) 2013-12-30
NZ711144A (en) 2017-01-27
EP2707504A1 (en) 2014-03-19
US10086072B2 (en) 2018-10-02
US20140141983A1 (en) 2014-05-22
IL229120B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112013028808A2 (pt) métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
CR20110128A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
SG195191A1 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
BRPI1011025A8 (pt) Métodos para o diagnóstico de distúrbios metabólicos usando transferidores epimetabólicos, moléculas intracelulares multdimensionais ou influenciadores ambientais
CA2851280C (en) Micrornas in neurodegenerative disorders
MX2016002987A (es) Biomarcadores de expresion de genes con sensibilidad a laquinimod.
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
BR112017017076A2 (pt) inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
WO2009068659A3 (en) Novel disease treatment by predicting drug association
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
IN2015DN00450A (pt)
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112015025944A8 (pt) composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
EP3019017A4 (en) Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
BRPI0717760A2 (pt) Métodos para tratar um distúrbio relacionados à angiogênese, para prover uma terapia adjuvante pós-operatória, para sensibilizar a vasculatura tumoral a um decréscimo no vegf, para inibir o recrescimento tumoral em um indivíduo e para reduzir a freqüência de administração do agente de quimioterapia ou da radiação a um indivíduo, e, kit
BR112015005583A2 (pt) método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements